Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElitePhysiqMD vs Harbor

ElitePhysiqMD
Graded #154

Lower grade

vs+4.200000000000003
Harbor
Graded #86

Higher grade

The verdict

Harbor takes it — 72/100 to 67.8/100.

Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueElitePhysiqMD +1
75
74
Dose & formulationEven
64
64
Clinical oversightHarbor +10
79
89
Labs & monitoringHarbor +11
52
63
FulfillmentHarbor +12
69
81
Contract termsElitePhysiqMD +8
55
47
ElitePhysiqMD · left barHarbor · right bar

The numbers

MetricElitePhysiqMDHarbor
WeighScore67.8/10072/100
GradeCC
Scorecard rank#154#86
Semaglutide$145/mo (starting dose, compounded)$99/mo (starting dose, compounded)
Tirzepatide$315/mo (starting dose, compounded)$149/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
ElitePhysiqMD

Graded #154 · C

Strengths

  • Compounded semaglutide from $145/mo subscription with no video calls and cancel-anytime policy
  • LegitScript certified, HIPAA-compliant; prescriptions from board-certified physicians via 5-min online assessment
  • Medications from US-licensed 503A/503B compounding pharmacies, shipped discreetly in 5–7 business days
  • HSA/FSA eligible; accepts all 50 states with no insurance required
  • Peptide therapy also available: NAD+, sermorelin, CJC-1295/ipamorelin, GHK-Cu, and glutathione

Where it loses points

  • Required $49 telehealth visit is added to every order, increasing effective monthly cost above the headline price
  • No labs disclosed; medication plans don't appear to include bloodwork or baseline testing
  • No dietitian, coaching, or nutrition support mentioned; program is medication-only
  • Tirzepatide subscription price ($315/mo) is above the mid-range for compounded tirzepatide
  • Newer platform (founded late 2025); no Trustpilot rating or public patient reviews found
Harbor

Graded #86 · C

Strengths

  • Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
  • LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
  • 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
  • 12-Month Money Back Guarantee if you don't reach your weight-loss goal
  • HSA/FSA eligible; no hidden fees, no insurance billed

Where it loses points

  • Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
  • Dietitian support offered only post-program (maintenance phase), not during active treatment
  • State-specific consultation types vary; nationwide availability unconfirmed for all states
  • No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
  • Newer brand; success rate and member counts are on-site claims, not third-party verified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard